Cargando…

Beta Cell Formation in vivo Through Cellular Networking, Integration and Processing (CNIP) in Wild Type Adult Mice

Insulin replacement therapy is essential in type 1 diabetic individuals and is required in ~40-50% of type 2 diabetics during their lifetime. Prior attempts at beta cell regeneration have relied upon pancreatic injury to induce beta cell proliferation, dedifferentiation and activation of the embryon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doiron, Bruno, Hu, Wenchao, DeFronzo, Ralph A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421132/ https://www.ncbi.nlm.nih.gov/pubmed/26696016 http://dx.doi.org/10.2174/1389201017666151223124031

Ejemplares similares

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

In Vivo Actions of Peroxisome Proliferator–Activated Receptors: Glycemic control, insulin sensitivity, and insulin secretion
por: Eldor, Roy, et al.
Publicado: (2013)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

Pathogenesis of Insulin Resistance in Skeletal Muscle
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
por: Liu, Jiwen (Jim), et al.
Publicado: (2012)

Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2013)

PSUN299 GLP-1 Contribution to Insulin Secretory Response to Protein Ingestion and Insulin Kinetics Following Gastric Bypass and Sleeve Gastrectomy
por: Rayas, Maria, et al.
Publicado: (2022)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

201 Effects of GLP-1 on Glucose and Islet-Cell Secretory Responses to Protein Ingestion After Gastric Bypass or Sleeve Gastrectomy
por: Rayas, Maria S., et al.
Publicado: (2022)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2008)

Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
por: Gaggini, Melania, et al.
Publicado: (2013)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2013)

The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells
por: Norton, Luke, et al.
Publicado: (2014)

Increased lipid availability for three days reduces whole body glucose uptake, impairs muscle mitochondrial function and initiates opposing effects on PGC-1α promoter methylation in healthy subjects
por: Eldor, Roy, et al.
Publicado: (2017)

The Impact of Vitamin D Deficiency on Retinopathy and Hearing Loss among Type 2 Diabetic Patients
por: Bener, Abdulbari, et al.
Publicado: (2018)

Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
por: Mehta, Rucha J., et al.
Publicado: (2019)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Impaired bone formation in ovariectomized mice reduces implant integration as indicated by longitudinal in vivo micro-computed tomography
por: Li, Zihui, et al.
Publicado: (2017)

Minimal Contribution of Fasting Hyperglycemia to the Incidence of Type 2 Diabetes in Subjects With Normal 2-h Plasma Glucose
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype
por: Jenkinson, Christopher P., et al.
Publicado: (2015)

Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials
por: DeFronzo, Ralph A., et al.
Publicado: (2016)

Formation and Degradation of Beta-casomorphins in Dairy Processing
por: Nguyen, Duc Doan, et al.
Publicado: (2015)

Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
por: Chavez, Alberto O., et al.
Publicado: (2009)

Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
por: Kanat, Mustafa, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pdp6gfehfsatm14bcluab7p8n1